Standout Papers

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/G... 2017 2026 2020 2023 355
  1. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma (2017)
    Sunil R. Hingorani, Lei Zheng et al. Journal of Clinical Oncology

Citation Impact

1 by Nobel laureates 2 from Science/Nature 60 standout
Sub-graph 1 of 21

Citing Papers

The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics
2024 Standout
Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer
2024 Standout
2 intermediate papers

Works of Wilson Wu being referenced

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma
2017 Standout

Author Peers

Author Molecular Biology Oncology Hepatology Cancer Research Immunology Last Decade Papers Cites
Wilson Wu 84 310 2 109 101 13 377
J.S. Alsumait 1 5 399
Claudia Heindl 2 63 23 705
F. C. Wagner 4 396
Tetsuya Uchiyama 18 1 21 946
Dan Jurca 1 25 298

All Works

Loading papers...

Rankless by CCL
2026